ArticleOncology letters2017
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion.Experimental hematology & oncology · 2026Article
- STAT3/p-STAT3 expression is correlated with clinicopathological characteristics and prognosis in non-small cell lung cancer.Histology and histopathology · 2025Article
- SIRPG promotes lung squamous cell carcinoma pathogenesis via M1 macrophages: a multi-omics study integrating data and Mendelian randomization.Frontiers in oncology · 2024Article
- JAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer.Cancers · 2023Article
- High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.Cancer medicine · 2023Article
- Discovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung.Cureus · 2022Article
- The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis.Oncogene · 2021Article
- Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.Journal of cellular and molecular medicine · 2021Article
- Comprehensive Analysis of Immune Implication and Prognostic Value ofFrontiers in oncology · 2021Article
- Development of a novel prognostic score combining clinicopathologic variables, gene expression, and mutation profiles for lung adenocarcinoma.World journal of surgical oncology · 2020Article
- miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.Journal of biosciences · 2020Article
- [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activation of Janus kinase 1 (JAK1) has been reported to occur in non-small cell lung cancer (NSCLC), activating the JAK/signal transducers and activators of transcription cascade. However, the association between JAK1 activation and the prognostic value in NSCLC remains unclear. The present study initially investigated the association between expression of the activated form of JAK1 (p-JAK1) and prognosis in patients with NSCLC. A cohort of 142 resected primary NSCLC tissue samples, including 74 adenocarcinoma (ADCC) and 68 squamous cell carcinoma samples, were analyzed. p-JAK1 expression status was determined by immunohistochemistry. Evaluation of epidermal growth factor receptor (EGFR) gene amplification by fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.